December 2025 – Page 8

Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech

Enliven Therapeutics Announces New CEO

1 month ago talkbio0Tagged CEO, ELVN, Enliven Therapeutics, Leadership, Myeloid Leukemia, Chronic, Phase 3 trial, Richard Fair, Rick Fair, Transition Mutation

Enliven Therapeutics; ELVN; new CEO; Rick Fair; Richard Fair; Sam Kintz; leadership transition; Phase 3 trial; ELVN-001; chronic myeloid leukemia; CML; biotech; Nasdaq ELVN

NiKang Therapeutics Presents NKT5097: First-in-Class CDK2/4 Dual Degrader at SABCS 2025

1 month ago talkbio0Tagged Cancer Therapeutic Procedure, CDK2/4 degrader, Malignant neoplasm of breast, NiKang Therapeutics, SABCS

NiKang Therapeutics; NKT5097; CDK2/4 degrader; SABCS 2025; cancer therapy; breast cancer

Pfizer’s Tukysa Shows Strong PFS Benefit in First-Line HER2+ Breast Cancer Maintenance at SABCS 2025, Sparking Debate with Enhertu

1 month ago talkbio0Tagged Enhertu, first-line maintenance, HER2-positive carcinoma of breast, HER2CLIMB-05, Pfizer, Progression-Free Survival, SABCS, Tukysa

Tukysa; Pfizer; HER2-positive breast cancer; SABCS 2025; HER2CLIMB-05; progression-free survival; Enhertu; first-line maintenance

Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported

1 month ago talkbio0Tagged Abnormal, aspects of adverse effects, Dysesthesia, Eli, Eli Lilly, Gastric Inhibitory Polypeptide, glucagon, Glucagon-Like Peptide 1, Obesity, Phase III, retatrutide, safety signal, sense of, Therapeutic tactile stimulation, triple agonist, triple hormone receptor agonist, TRIUMPH-4, Weight Loss

Eli Lilly; retatrutide; triple agonist; triple hormone receptor agonist; GLP-1; GIP; glucagon; obesity; weight loss; TRIUMPH-4; Phase III; dysesthesia; abnormal sense of touch; safety signal; side effects

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

1 month ago talkbio0Tagged ARIA risk, Binding action, Biological Markers, clinical outcomes, Dental Plaque, oligomer selectivity, Phase 1b Trial, PMN310, PRECISE-AD trial, ProMIS Neurosciences, Toxic Oligomers, vascular deposit binding

ProMIS Neurosciences; PMN310; toxic oligomers; ARIA risk; PRECISE-AD trial; peer-reviewed publication; oligomer selectivity; plaque binding; vascular deposit binding; phase 1b trial; biomarkers; clinical outcomes